About Us

Board of Directors

Our board members have extensive experience in the pharmaceutical industry, and their guidance helps us bring important therapeutics to patients in need.

Barbara Deptula
Former Executive Vice President and Chief Corporate Development Officer of Shire plc.
Barbara Deptula has been a director since September 2013. Ms. Deptula brings to the AMAG board broad-based corporate development expertise obtained through her distinguished 30-year career in a...
Barbara Deptula has been a director since September 2013. Ms. Deptula brings to the AMAG board broad-based corporate development expertise obtained through her distinguished 30-year career in a variety of biotechnology and multi-national pharmaceutical organizations. Ms. Deptula began working at Shire plc in 2004 and retired in 2012 from her position as executive vice president and chief corporate development officer, and as a member of Shire’s leadership team. Prior to joining Shire, Ms. Deptula was president of the biotechnology division of Sicor, Inc. and senior vice president for commercial and product development at Coley Pharmaceutical Group. She also held senior management positions focused on marketing, product development, licensing and business development at US Bioscience, Schering Plough, American Cyanamid, and Genetics Institute. Ms. Deptula received a Bachelor of Science degree from the School of Pharmacy at University of Connecticut and a Master of Business Administration from the University of Chicago.
John A. Fallon, M.D.
Former Senior Vice President and Chief Physician Executive at Blue Cross & Blue Shield of Massachusetts
John Fallon, M.D. has been a director since September 2014. Dr. Fallon most recently served as senior vice president and chief physician executive at Blue Cross & Blue Shield of Massachusetts...
John Fallon, M.D. has been a director since September 2014. Dr. Fallon most recently served as senior vice president and chief physician executive at Blue Cross & Blue Shield of Massachusetts (BCBSMA) from 2004 to 2015. Prior to his role at BCBSMA, Dr. Fallon served as chief executive officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts. He serves as lead director on the board of directors of Insulet Corporation, and serves on the board of directors for Exact Sciences. He also serves on several not-for-profit boards, including Network for Excellence in Health Innovation (Chair), National Committee for Quality Assurance Medical Standards (Chair), New England Comparative Effectiveness Public Advisory Council and Temple University School of Medicine Board of Advisors. Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians. He received a Bachelor of Science degree from the College of the Holy Cross, a Master of Business Administration from the University of South Florida and a Doctor of Medicine degree from Tufts University School of Medicine.
William K. Heiden
President and Chief Executive Officer of AMAG Pharmaceuticals, Inc.
William Heiden has been a director since May 2012. Mr. Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer of AMAG since May 2012 and served as...
William Heiden has been a director since May 2012. Mr. Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer of AMAG since May 2012 and served as president from May 2012 through April 2015. Mr. Heiden joined AMAG from GTC Biotherapeutics, Inc. (now rEVO Biologics, Inc.), where he was president and chief executive officer from 2010 to 2012 and chairman of the board of directors from 2007 to 2013. From 2004 to 2008, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals. Prior to that, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (now GlaxoSmithKline plc). Mr. Heiden also held various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. He currently serves on the board of directors for Atara Biotherapeutics, Inc. Mr. Heiden holds a Bachelor of Arts degree from the University of Florida, a Master of Information Management from the University of Louvain, and a Master of Business Administration from Cornell University’s Johnson Graduate School of Management.
Robert J. Perez
Managing Partner, Vineyard Sound Advisors
Robert Perez has been a director since January 2009. Mr. Perez is the founder and has been the managing partner of Vineyard Sound Advisors since 2015. He formerly served as president and chief...
Robert Perez has been a director since January 2009. Mr. Perez is the founder and has been the managing partner of Vineyard Sound Advisors since 2015. He formerly served as president and chief executive officer of Cubist Pharmaceuticals, Inc. Mr. Perez joined Cubist in 2003, as senior vice president, sales and marketing and led the launch of Cubicin® (daptomycin for injection). Prior to joining Cubist, he served as vice president of Biogen, Inc.’s CNS Business Unit from 2001 to 2003, where he was responsible for commercial leadership of an $800 million neurology business unit and held positions of increasing responsibility within the commercial organization from 1995 to 2001. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez is currently a member of the board of trustees of the Dana-Farber Cancer Institute, Inc. and the board of advisors of the Citizen School of Massachusetts. Mr. Perez serves on numerous boards including Zafgen, Inc., Flex Pharma, Inc., Cidara Pharmaceuticals, College Bound Dorchester, and the Biomedical Science Careers Program. Mr. Perez received a Bachelor of Science degree from California State University, Los Angeles and a Master of Business Administration from The Anderson School at UCLA.
Lesley Russell, M.D.
Former Chief Medical Officer, Innocoll Holdings plc
Lesley Russell, M.D. has been a director since December 2009. Dr. Russell served as chief medical officer of Innocoll Holdings from April 2016 until November 2017. She previously served as the chief...
Lesley Russell, M.D. has been a director since December 2009. Dr. Russell served as chief medical officer of Innocoll Holdings from April 2016 until November 2017. She previously served as the chief operating officer of TetraLogics Pharmaceuticals from August 2013 until April 2016. Prior to TetraLogics, she was the senior vice president and global head of research and development for Teva Pharmaceuticals, Inc., a role which she was appointed to after Teva acquired Cephalon. While at Cephalon from 2006 to 2011, Dr. Russell served as executive vice president and chief medical officer. Prior to joining Cephalon in 2000, Dr. Russell worked for several pharmaceutical organizations, including US Biosciences, Eli Lilly and Company and Amgen. Before joining the pharmaceutical industry, she was trained in hematology/oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children in Edinburgh, UK, and was a Research Fellow at University of Edinburgh Faculty of Medicine. Dr. Russell currently serves on the board of directors of Endoycte, Inc. and Enanta Pharmaceuticals. Dr. Russell received Bachelor of Medicine and Bachelor of Surgery degrees from the University of Edinburgh. She is a member of the Royal College of Physicians and is registered with the General Medical Council.
Gino Santini
Chairman of the Board, AMAG; Retired Eli Lilly and Company Executive
Gino Santini has been a director since February 2012 and chairman of the board since April 2014. In 2010, Mr. Santini retired from a distinguished career with Eli Lilly and Company that spanned...
Gino Santini has been a director since February 2012 and chairman of the board since April 2014. In 2010, Mr. Santini retired from a distinguished career with Eli Lilly and Company that spanned nearly three decades. During his tenure at Eli Lilly and Company, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, senior vice president of corporate strategy and policy, president of U.S. operations, and president of the women's health franchise. Mr. Santini capped his career at Eli Lilly and Company as a member of the company’s executive committee and as the Senior Vice President of Corporate Strategy and Business Development. Mr. Santini currently serves on the boards of directors of Intercept Pharmaceuticals, Inc., Intarcia Therapeutics, Inc., Sorin, Collegium Pharmaceuticals, Inc., Allena Pharmaceuticals, Inc., and Artax Biopharma Inc. In addition, Mr. Santini serves on the board of directors for Vitae Pharmaceuticals, Inc. where he is also the chair of the  nominating and governance committee, as well as Horizon Pharma, Plc. where he is also chair of the transactions committee. Mr. Santini is fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a Master of Business Administration from the University of Rochester.
Davey S. Scoon, CPA
Non-Executive Chairman, Board of Directors Tufts Health Plan
Davey Scoon has been a director since December 2006. Mr. Scoon has more than 30 years of experience in finance and administration in executive positions. From 2003 to 2005, Mr. Scoon was chief...
Davey Scoon has been a director since December 2006. Mr. Scoon has more than 30 years of experience in finance and administration in executive positions. From 2003 to 2005, Mr. Scoon was chief administrative and financial officer of Tom’s of Maine, a company that manufactures natural care products. From 2001 to 2003, Mr. Scoon served as chief financial and administrative officer for Sun Life Financial U.S. and from 1999 to 2001, Mr. Scoon served as vice president and chief financial officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities including chief financial officer and chief operating officer. Mr. Scoon served as chairman of the board of directors of Tufts Health Plan as a director from 1981 to 2015. He currently serves as chairman of the board of trustees of Allianz Funds and is a member of the board of directors of Biodel Inc. He has been an Adjunct Professor at the University of Wisconsin-Madison School of Business since 2010. Mr. Scoon holds a Bachelor of Business Administration from the University of Wisconsin and a Master of Business Administration from Harvard Business School, and is a Certified Public Accountant.
James Sulat
Former Chief Executive Officer and Chief Financial Officer at Maxygen, Inc.
James Sulat has been a director since April 2014. Mr. Sulat served as the chief executive officer and chief financial officer of Maxygen, Inc. from 2009 to 2013, and as a member of its board of...
James Sulat has been a director since April 2014. Mr. Sulat served as the chief executive officer and chief financial officer of Maxygen, Inc. from 2009 to 2013, and as a member of its board of directors from 2003 to 2013. From 2005 to 2009, Mr. Sulat served as president and chief executive officer and then as chief financial officer of Memory Pharmaceuticals Corporation, as well as a member of its board of directors. Prior to these roles, Mr. Sulat was the chief financial officer in several different large and mid-sized public companies. Mr. Sulat serves as chairman of the board of directors for Momenta Pharmaceuticals, Inc., and serves on the board of directors of Arch Therapeutics, Inc., Diadexus, Inc., and Valneva SE. Mr. Sulat received a Bachelor of Science in Administrative Sciences from Yale University, and a Master of Business Administration and a Master of Science in Health Services Administration from Stanford University.